Letrozole

Letrozole works by selectively and reversibly inhibiting the aromatase enzyme, which converts adrenal and ovarian androgens into estrogens. This inhibition leads to a marked reduction in circulating estrogen levels, depriving estrogen‑dependent cancer cells of a key growth signal.

The dosage of Letrozole is determined by the prescribing clinician based on the patient’s condition, disease stage, and treatment protocol. Typical regimens involve a once‑daily oral tablet, but the exact strength and schedule are set by the healthcare provider.

Letrozole is classified as Pregnancy Category X, indicating it is contraindicated during pregnancy due to known teratogenic risk. It is also not recommended for breastfeeding women because it may pass into milk and affect the infant.

To order Letrozole, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required cold‑chain handling), and import documentation.

Letrozole, anastrozole, and exemestane belong to the same class of aromatase inhibitors. Letrozole is often chosen for its potent and sustained estrogen suppression, while anastrozole has a similar efficacy profile with a slightly different side‑effect spectrum. Exemestane is a steroidal inhibitor and may be preferred in patients who have progressed on non‑steroidal agents.

Letrozole tablets should be stored at ambient temperature, below 25 °C, in their original blister or container to protect from moisture and light. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Letrozole is taken orally as a tablet, usually with a glass of water. It can be taken with or without food, but consistency in administration (same conditions each day) helps maintain stable drug levels.

Serious risks include severe liver injury, osteoporotic fractures, deep‑vein thrombosis or pulmonary embolism, and rare but life‑threatening allergic reactions. Patients should be monitored for signs of hepatic dysfunction, bone density loss, and any sudden cardiovascular symptoms.

Letrozole is contraindicated in premenopausal women, pregnant or breastfeeding individuals, and patients with known hypersensitivity to the drug. It should also be avoided in patients with uncontrolled liver disease or a history of severe thromboembolic events unless the benefits outweigh the risks.